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      In recent years, a large volume of medical and public health literature has 
been dedicated to the sexually transmitted infection Human Papillomavirus 
(HPV). The purpose of this paper is to provide a comprehensive assessment of 
recent empirical investigations which assess the public health impact of HPV 
and recent HPV vaccinations.
Epidemiologic Assessment
 Human Papillomavirus is the most common sexually transmitted 
infection in the United States (U.S.; Weinstock, Berman, & Cates, 2004). It 
is estimated that 20 million people are currently infected with HPV and that 
an additional 6 million new infections occur every year (Centers for Disease 
Control and Prevention [CDC], 2009). Human Papillomavirus is a small DNA 
virus that replicates in squamous epithelial cells found on the skin, cervix, 
vagina, anus, vulva, head of the penis, mouth, and throat (Widdice & Kahn, 
2006). It is passed from person-to-person via sexual intercourse or skin-to-skin 
contact and can infect both men and women (Baseman & Koutsky, 2005). In 
most cases, infections with HPV are not serious and are usually asymptomatic, 
transient, and resolve without treatment (Baseman & Koutsky, 2005). 
However, in some individuals HPV infections result in genital warts, cervical 
abnormalities, and/or various cancers (CDC, 2009; Worden et al., 2008). Since 
there are often no signs or symptoms of infection many individuals are unaware 
of their possible transmission to others (CDC, 2009). It is estimated that 80% 
of sexually active women will have acquired HPV by the age of 50 with a high 
prevalence occurring from ages 14-19 (Datta et al., 2008; Myers, McCrory, 
Nanda, Bastian, & Matchar, 2000). According to Manhart and colleagues (2006) 
the prevalence of infection among women aged 18-25 increases from 14.3% 
among those with one lifetime sexual partner to 31.5% with more than three 
partners.
 There are more than 100 different strains of HPV and many differ in 
terms of the epithelium they infect. Some infect cutaneous sites whereas others 
infect mucosal surfaces (Trottier & Franco, 2006). Over 40 strains are sexually 
transmitted and can cause genital warts, cervical abnormalities, and/or cancer of 
the oral cavity, oropharynx, anus, vulva, penis and vagina (CDC, 2009). The 
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incidence of HPV-associated cancers/year is as follows: 12,000 cervical, 4,400 
anal, 2,700 vulvar, 1,000 vaginal, and 1,000 penile (CDC, 2009). The strains 
of HPV that cause cervical cancer differ from those that cause genital warts 
(Munoz, Bosch, & deSanjose, 2003). Strains 16 and 18 are considered high risk 
and have been detected in 99.7% of cervical cancer cases. Strains 6 and 11 are 
considered low risk and account for 90% of genital wart cases. Most genital 
infections will naturally clear without medical intervention (Munoz et al., 2003). 
However, women who do not clear high risk strains are at an increased risk for 
cervical cancer. 
 Human Papillomavirus causes cells on or around the cervix to become 
abnormal and may progress to pre-cancerous stages (Collins, Mazloomzadeh, & 
Winter, 2002). Many women may develop mild cytologic abnormalities causing 
atypical squamous cells of undetermined significance (ASC-US) or low-grade 
squamous intraepithelial lesions (LGSIL) as detected on a Papanicolau (Pap) 
test (Munoz et al., 2003). In the U.S., approximately 4% to 5% of all cervical 
cytology results are ASC-US (Munoz et al., 2003). These abnormal cells may 
clear without treatment and most high-risk HPV infections do not result in 
cancer (Munoz et al., 2003). Persistent infection is associated with adaptations 
that can result in pre-cancer cells. True pre-cancer cell changes are called high 
grade squamous intraepithelial lesions (SIL). Pap tests are used to identify 
cervical cancer precursors that can be treated before progression to cervical 
cancer occurs. The American Congress of Obstetricians and Gynecologists 
(ACOG) recommends women start having Pap tests approximately three years 
after the onset of vaginal intercourse but no later than age 21 (ACOG, 2003).
 Selected strains of HPV can also cause genital warts. There is an 
estimated 1 million new cases of genital warts each year in the U.S. (Kodner & 
Nasraty, 2004). Genital warts are usually soft, flesh-colored growths that can 
be raised or flat, small or large, alone or in clusters. They sometimes disappear 
without treatment or may need to be removed by burning, freezing, laser or 
surgical procedures. However, they can return after treatment because the viral 
infection may be persistent.  It is estimated that 25% of cases reoccur within 
three months (Kodner & Nasraty, 2004). 
 The high prevalence rates of HPV-related strains have generated public 
health interest in primary prevention methods focused upon risk reduction. 
Transmission of HPV can be reduced through the correct and consistent use of 
physical barriers such as male latex condoms (Winer et al., 2006). While HPV 
can occur in areas that are not covered or protected by a condom, the use of 
condoms has been associated with decreases in HPV-related problems. A study 
conducted by Winer and colleagues (2006) assessed the relationship between 
HPV infection and vaginal intercourse among 82 university students over an 
eight month period. Results indicated that the participants who used condoms on 
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all sexual occasions exhibited an incidence of genital HPV of 37.8/100 patient-
years, whereas participants who used male condoms less than 5% of the time 
had a rate of 89.3/100 patient-years.
According to the CDC (2010a): 
 Condom use may reduce the risk for HPV-associated diseases    
 (e.g., genital warts and cervical cancer) and may mitigate the other   
 adverse consequences of infection with HPV; condom use    
 has been associated with higher rates of regression     
 of cervical intraepithelial neoplasia (CIN) and clearance of    
 HPV infection in women, and with regression of     
 HPV-associated penile lesions in men.
 In 2006, Merck Pharmaceuticals introduced a new vaccine titled 
Gaurdasil® that helps to protect against HPV strains 6, 11, 16, and 18. The 
prophylactic vaccine is made from non-infectious HPV L1 proteins and is 
administered through a series of three intramuscular injections (.5-ml doses) 
over a six month period (0, 2, and 6 months; CDC, 2007). Currently, the vaccine 
is licensed for females and males ages 9 to 26 and costs $360 for the full series 
(Food and Drug Administration [FDA], 2010; Harris, 2006). A second vaccine, 
Cervarix®, was submitted to the FDA in 2008 and is currently available as a 
bivalent vaccine that protects against HPV 16 and 18 (Lowy & Schiller, 2006).  
The public health benefits of the vaccines would be expected to significantly 
reduce HPV-related morbidity and mortality and reduce the overall economic 
burden upon health care systems (De Melo-Martin, 2006). The vaccines 
represent a major step toward the prevention of HPV and cervical cancer but 
should not be used as a replacement for other prevention strategies such as 
cervical cancer screenings or protective sexual behaviors.  
 The prevalence of HPV infection is high among college women and 
young adults 20 to 24 years of age (Dunne, Unger, & Sternberg, 2007; Winer, 
Lee, & Hughes, 2003). College women have a high risk of acquiring HPV when 
compared to the general population because of their high-risk sexual behaviors 
(Dunne et al., 2007; Winer et al., 2003). Dinger and Parsons (1999) studied 
college students living in residence halls and in fraternity/sorority housing at 
a northwestern university. Results indicated that 39.4% of students living in 
fraternity/sorority housing reported having 6 or more sexual partners compared 
to 22.8% of students living in residence halls. In addition, 15% of students 
living in fraternity/sorority housing reported more than 20 acts of sexual 
intercourse prior to the study compared to 5% of students living in residence 
halls. According to the CDC (1997), only 29.6% of sexually active students 
reported that they or their partner used condoms during their last act of sexual 
intercourse. 
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Barriers to Vaccination Acceptance
 Recent studies have begun to focus upon the examination of potential 
barriers to mandatory HPV vaccination as well as overall acceptance of the 
vaccine by target populations. A solid understanding of potential barriers is 
crucial for health care providers to enable them to effectively assist parents and 
adolescents in their decisions regarding the vaccines (Zimet, 2009). Research 
indicates that school-entry requirements of vaccinations have proven to be a 
very efficacious method of protecting a large majority of school children from 
vaccine-preventable diseases (Hinman, Orenstein, Williamson, & Darrington, 
2002). Though the school-entry requirements for childhood vaccines vary from 
state to state, every state offers parents the option to opt-out for medical reasons 
and some allow exceptions based on religious or philosophical beliefs (Zimet, 
2009). Studies also demonstrate that increased outbreaks of preventable diseases 
occur when vaccination requirements are relaxed (Feikin et al., 2000; Omer et 
al., 2006;Thompson et al., 2007). Controversy surrounding the quadrivalent 
HPV vaccine received increased media attention when several states proposed 
legislative efforts that would mandate HPV vaccination for girls entering middle 
school (Zimet, 2009).
  On February 2, 2007 Texas became the first state to mandate HPV 
vaccination, requiring all girls to receive Gardasil® before entering 6th grade 
(Cook, 2008). By March 2007, legislation had been introduced in 41 states and 
the District of Columbia to “require, fund, or educate the public about the HPV 
[v]accine” (Cook, 2008, p. 213-214). Of these, 24 states required vaccination 
for enrollment in school, while the remaining 17 proposed policies that were 
centered upon funding the vaccine or sponsoring education-based programs 
(Cook, 2008). 
 Many parents view the efforts as an infringement upon their rights 
and are weary of the safety and efficacy of the vaccine (Cook, 2008). Dissent 
regarding school-entry vaccination requirements is centered upon the following 
key arguments (a) currently, long-term safety and accessibility issues have not 
been empirically assessed (b) fear that vaccination will promote increased sexual 
activity among young girls and adolescents and (c) the vaccination will provide 
a false sense of reduced susceptibility from other sexually transmitted infections 
(Blumenthal, Heyman, Trocola, & Slomovitz, 2008).
 Although few laws pertaining to school-entry requirements have been 
enacted, research suggests that HPV vaccination utilization remains higher than 
comparable non-mandated vaccines for preventable communicable diseases 
(Jain, Stokley, & Yankey, 2008; Zimet, 2009).
  In 2007, approximately 25% of 13-17 year old girls in the U.S. received 
at least one dose of HPV vaccine and an estimated 68% of first dose 
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recipients received at least two doses at the time of follow-up (Jain et al., 2008). 
In contrast, a United Kingdom (U.K.) study of 2,817 girls attending 36 schools 
found that nearly 71% received the first dose and 97% of first dose recipients 
received the second (Brabin et al., 2008). Australian studies yield similar results 
of high vaccine acceptance, with 3-dose uptake at 75 - 80% (Garland, 2008). 
 Another Australian study conducted by Fairley and colleagues (2009) 
examined proportions of new clients presenting with genital warts beginning 
in 2004 before vaccination programs were implemented in 2007 (Fairley et al., 
2009). In 2007, school-based and general practice programs began offering free 
quadrivalent vaccination for school girls aged 12-18 years and women less than 
26 years of age. In the period from 2004 – 2007, there was an increase in new 
clients presenting with genital warts of 1.8% (95% CI 0.2% - 3.4%) per quarter 
in women under 28 years of age. In comparison, there was a decrease of 25.1% 
(95% CI 30.5% - 19.3%) in the proportion of women under 28 years presenting 
with warts per quarter in 2008. The average quarterly change for heterosexual 
men was a decrease of 5% (95% CI 0.5% -- 9.4%; p = .031). These findings 
demonstrate that Australian and U.K. school-based vaccination approaches are 
more effective than the U.S. clinic based-approach (Zimet, 2009). 
 Worldwide acceptance of the vaccines is increasing. As of September 
2008, over 100 countries had licensed the quadrivalent vaccine and over 75 
countries had licensed the bivalent vaccine (Irwin, 2008). Unfortunately, there 
is a vast amount of misunderstanding and misperception regarding HPV and 
cervical cancer. In general, young women, parents, and health care providers 
appear to be interested in vaccines that prevent HPV, but there are varying 
degrees of acceptance among the populations (Zimet, 2005). Recent studies of 
physician attitudes regarding vaccination recommendations have revealed that 
acceptance rates of physicians generally increased with the girl’s age (Mays & 
Zimet, 2004; Raley, Followwill, Zimet, & Ault, 2004; Riedesel et al., 2005).  
In 2005, Daley and colleagues (2006) conducted a national assessment of 
vaccination-related attitudes among 294 U.S. pediatricians. Results indicated 
that pediatricians believed that if a future vaccination was developed and 
endorsed by a health-related organization, they would increasingly be willing 
to recommend the vaccine to girls and boys based upon age. Vaccination 
recommendation rates ranged from 46% (ages 10 to 12) to 89% (ages 16 to 
18) in girls as well as 37% (ages 10 to 12) to 82% (ages 16 to 18) in boys. In 
addition, only 11% of participants believed that the vaccine would encourage 
sexual behavior among their patients (Daley et al., 2006). Other factors that 
could influence acceptance beliefs include the potential economic and personal 
benefits associated with decreased health care costs and stress due to abnormal 
Pap results (Blumenthal et al., 2008; Harper, 2004). 
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 Studies reveal that sexually active college students ages 20 to 24 
often lack knowledge regarding HPV and become more aware only after being 
diagnosed with HPV infection by a health care provider (Vail-Smith & White, 
1992; Yacobi, Tennant, Ferrante, Pal, & Roetzheim, 1999).  Previous studies 
have shown that 85% of college women have heard of HPV but are unaware of 
the infectivity and overall prevalence of the virus (Vail-Smith & White, 1992; 
Yacobi et al., 1999). A study by Lambert (2001) focused on college women’s 
knowledge of HPV. The women were given a pre-questionnaire, participated in 
a brief HPV-focused educational intervention, and were reevaluated 3 months 
later.  Results showed that the women answered 45% of the HPV questions 
correctly pre-intervention and 78% correctly post-intervention. These findings 
suggest that targeted intervention efforts may increase general knowledge in 
specific populations potentially leading to adoption of preventative methods 
such as receiving a vaccine. 
 Only 30% of women participants in two U.K. studies, as well as 13% 
of adolescents in a Canadian study, had prior knowledge of HPV (Dell, Chen, 
Ahmad, & Stewart, 2000; Pitts & Clark, 2002; Waller et al., 2003). Additional 
research has shown that even among those who had prior knowledge of HPV, 
many misunderstandings concerning infection, cervical cancer screening, and 
Pap smears exist (Zimet, 2005). One investigation indicated that 86% of women 
interested in learning about the virus believed that HPV-related educational 
materials should be distributed to individuals before they initiate sexual activity 
(Holcomb, Bailey, Crawford, & Ruffin, 2004). Another study of male and 
female university students revealed that 74% of participants were willing to 
receive the vaccine (Boehner, Howe, Bernstein, & Rosenthal, 2003). There were 
no differences in acceptance rates based on gender or motivation for vaccination 
(i.e., as an STI vaccine versus a reproductive health vaccine). Overall, this study 
suggests that HPV vaccination is generally viewed as positive by young men 
and women.
 One important public health aspect of HPV for collegiate students 
is the availability of the vaccinations within their health centers. A study 
conducted in 2001 by Koumans and colleagues (2005) at the CDC assessed 910 
colleges and universities nationally. Findings indicated that 60% of colleges and 
universities host a student health center/health services. Butler 2009) assessed 
the availability of the vaccine within 358 colleges and universities with student 
health centers nationally. Results indicated that 72.3% currently offer at least 
one form of the vaccine to their student population. Demographic characteristics 
(size of college/university, geographic region, as well as non-faith-based 
affiliation) were all significant factors in predicting vaccine availability. In 
addition, health center institutional complexity and formalization were also 
significant predictors.
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Age of Vaccination
 The 2009 Youth Risk Behavior Survey reported that 65.0% of 12th 
grade females had sexual intercourse; 52.5% of 11th grade; 39.6% of 10th grade; 
and 29.3% of 9th grade (CDC, 2010b). The median prevalence of having ever 
had sexual intercourse was 48.2% across state surveys (data ranged from 39.0% 
to 61.0%). More surprisingly, 5.9% of students nationwide reported having had 
sexual intercourse before the age of 13 and 8.8% of sexually active 9th graders 
reported having had 4 or more lifetime sex partners. Based upon these statistics, 
it is clear that HPV educational programs need to target younger populations 
and their parents in order to increase vaccination in adolescents before initial 
sexual activity which would greatly decrease their overall risk of cervical cancer 
(Blumenthal et al., 2008). 
 Promotion of early vaccination is also important because data shows 
that the efficacy and potential benefit of the vaccines is not as clear for women 
older than 19 years as it is for adolescents under the age of 19 (Saslow et al., 
2007). However, females over the age of 19 who have not yet engaged in sexual 
intercourse would still greatly benefit from the vaccine, and women aged 19 to 
26 could still benefit if they have not been exposed to all HPV vaccine types. 
The American Cancer Society (ACS) guidelines suggest that the three primary 
factors to consider when recommending age to vaccinate are duration of 
protection, age for optimal efficacy, and feasible plans for distribution (Saslow et 
al., 2007). Since the vaccines are relatively new, duration studies are limited and 
only include data from 3.5 to 5 years. The lower age limit for efficacy studies is 
16 years of age for Gardasil® and 15 years of age for Cervarix®. 
Differences between Specific Populations and Geographic Regions
 Another barrier to global vaccination utilization rates is that vaccine 
acceptance rates appear to differ among specific populations. One study revealed 
that Latina immigrants unanimously agreed upon acceptance while African 
Americans were more skeptical and cited concerns about effectiveness, side 
effects, and potential for an increase in sexual activity (Scarinci, Garc´es-
Palacio, & Partridge, 2007). A study in Mexico examined the effect of HPV 
education on vaccine acceptance (Lazcano-Ponce et al., 2001). After participants 
were educated about the preventative factors of the vaccine regarding cervical 
cancer, 84% of the women stated they would allow their teenage daughter to 
be vaccinated. The effect of brief educational efforts is demonstrated in another 
study which found that acceptance of the vaccine among parents of 10 to 
15-year-old children rose from 55% to 75% after they read an information sheet 
about HPV and vaccination; parents in opposition to the vaccine cited sexual 
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disinhibition as a barrier (Davis, Dickman, Ferris, & Dias, 2004).
  A separate review of studies of HPV beliefs in the United States found 
that only 6 - 12% of parents were concerned that vaccination would lead to 
increased sexual activity (Brewer & Fazekas, 2007). Furthermore, a study of 
parental acceptance in California found that 75% of parents would be likely 
to vaccinate a daughter before the age of 13 (Constantine & Jerman, 2007). 
In comparing non-Hispanic parents to other populations, Hispanic parents 
were more likely to accept vaccination, whereas African American and Asian-
American parents were less likely. An investigation in England conducted by 
Marlow, Waller, and Wardle (2007) revealed that 75% of mothers with children 
in primary and secondary school settings were acceptant of vaccination. In 
addition, mothers were found to be more acceptant of the vaccine if they were 
categorized into the following traits (a) experienced cancer in their family, (b) 
had older daughters, (c) had perceived approval from their spouse/significant 
other, and (d) viewed vaccine acceptance as normative.
Health System Disparities
 Other concerns are that current social and economic disparities 
within the health care system have led to poor and minority populations being 
disproportionately affected by cervical and other HPV-related cancers (Zimet, 
2009). In 2003, researchers from the International Agency for Research on 
Cancer conducted a meta-analysis of 57 studies which assessed the relationship 
between social inequality and cervical cancer risk (Parikh, Brennan, & Boffetta, 
2003). Results of the investigation revealed:   
 An increased risk of approximately 100 percent between high and low   
 social class categories for the development of invasive cervical cancer.   
 This increased risk was apparent in all geographic regions, although   
 it was stronger in Africa, Asia and Latin America and the Caribbean   
 than in Europe (Parikh, Brennan, & Boffetta, 2003, p. 687). 
 One of the most significant health disparities associated with cervical 
cancer is the lack of screening. Cervical screening is a highly effective 
prevention strategy that enables women to detect precancerous cervical 
abnormalities early on (Erdman, 2009). According to Erdman (2009), “social 
health disparities are unjust … because they result from government action that 
adversely affects the health risks and outcomes of groups already disadvantaged 
by virtue of their underlying social position” (p. 370 ). Governments all over 
the world are failing to implement health measures for underserved populations, 
thus creating health disparities and placing already disadvantaged populations 
at increased risk (Erdman, 2009). General Comment No. 14 from the United 
Nations Committee on Economic, Cultural, and Social Rights (CECSR) 
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explicitly states:
 Inappropriate health resource allocation can lead to discrimination   
 that may not be overt. For example, investments should    
 not disproportionately favour expensive curative health services which   
 are often accessible only to a small, privileged fraction of    
 the population, rather than primary and preventive     
 health care benefiting a far larger part of the population (2000).  
Increasing the availability of cancer screening programs for disadvantaged 
populations should be a high priority if the ultimate goal is to prevent worldwide 
HPV prevalence. 
Male Vaccination
 Other policies and health measures that would facilitate an overall 
HPV prevalence decrease are those directed specifically at males. If only 
women are vaccinated, statistics indicate that 75% of HPV cases caused by the 
four strains that the vaccine prevents would be prevented, whereas more than 
90% of cases would be prevented if both males and females are vaccinated 
(Cook, 2008). These statistics suggest that vaccinating males would be a very 
effective preventative method in terms of decreasing HPV prevalence, but 
some researchers are concerned with the cost-effectiveness of male vaccination 
programs. Furthermore, until more research is conducted that links HPV to 
cancer in men, acceptance and advocacy of male vaccination is unlikely. 
 Recent research conducted by Worden and colleagues (2008) shows a 
possible link between HPV and cancer of the tongue and tonsils in men. In their 
study, biopsies from 27 out of 42 (64.3%) oral cancer male and female patients 
tested positive for HPV16. Positive HPV16 results were associated with younger 
age (median, 55 v 63 years; p = .016), nonsmoking status (p = .037), and, most 
importantly, sex (22 of 30 males [73.3%] versus 5 of 12 females [41.7%]; p 
= .08). These results suggest that men with HPV infections have an increased 
risk for oral cancer. The team suggests that vaccinating both male and female 
adolescents should be considered because of the high risk of HPV associated 
cancers in men. Current estimates from the ACS report that HPV DNA is present 
in about one-third of oropharyngeal cancer cases and about one-half of tonsil 
cancer cases (ACS, 2010). Considering that men accounted for more than two-
thirds (20,100) of the estimated 28,500 Americans who contracted oral cancer 
in 2009, HPV vaccines for males could prove to be a very effective preventative 
method (ACS, 2010). 
 Other researchers are focusing on the effectiveness of HPV vaccination 
regarding the prevention of anal cancer in men (Lindsey, DeCristofaro, & James, 
2009). The HPV quadrivalent vaccine Gardasil® may also prove to be effective 
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for preventing anal cancer because the same four strains (types 6, 11, 16, and 
18) that are the most common precursors to the development of cervical cancer 
are also responsible for causing 80% of anal cancers (Lindsey et al., 2009). 
Therefore, anal cancer could become a vaccine-preventable disease if the HPV 
vaccine is effective for men (Lindsey et al., 2009). In a recent study of more than 
4,000 males ages 16-26, sponsored by Merck & Co., Gardasil® was found to be 
90.4% efficacious against HPV 6, 11, 16, and 18-related external genital lesions 
(EGL; Merck & Co, Inc., 2009). Proponents of male vaccination argue that it 
will also provide herd immunity which will ultimately significantly reduce the 
risk of cervical cancer in unvaccinated women (Nath & Thappa, 2009). Future 
research is needed to assess the causal role of HPV in various cancers as well as 
the potential beneficial outcomes associated with large-scale vaccination efforts 
in both male and female populations. 
Efficacy
 Efficacy analyses of the quadrivalent vaccine found that it was 98.2% 
(CI  = 93.5% - 99.8%) effective in protecting against HPV 16- or 18-related CIN 
2/3 or AIS and 96.0% (CI = 92.3% - 98.2%) effective in protecting against any 
CIN attributed to HPV 6, 11, 16 or 18 (FDA, 2010). Vaccine efficacy against 
HPV 6- and 11-related external genital warts was 99.0% (CI = 96.2% - 99.9%) 
and 100% (CI = 55.5 - 100.0) against HPV 16- or 18-related VIN 2/3.
The bivalent vaccine Cervarix® has also been proven to be highly effective 
(Harper et al., 2006). After investigators conducted a combined analysis, the 
results revealed that vaccine efficacy was 100% (95% CI, 42.4% -100%) in 
preventing HPV16 or HPV18-related CIN in a study of women aged 15 to 
25 years who received the recommended 3-dose vaccination regimen and 
participated in a 4.5 year (44 to 53 months) follow-up. In addition, other 
studies have found the bivalent HPV types 16, 18 vaccine to be more than 
90% efficacious against incident infection, 100% efficacious against persistent 
infection and 90.4% to 100% efficacious against HPV types 16, 18-related CIN 
(Harper et al., 2004; Harper et al., 2006; Paavonen et al., 2007). Furthermore, 
research shows the vaccine has more than 98% seropositivity after 4.5 years and 
that cross-protection exists with the bivalent HPV types 16, 18 vaccine against 
incident infection with HPV types 45 and 31 (Harper et al., 2006). 
Adverse Effects
 The future of HPV vaccination programs lies within current and 
developing research studies. While research supporting the effectiveness of the 
vaccines is the primary focus, reports on adverse effects of the vaccines 
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will also play an important role in whether overall acceptance from the general 
population, as well as from healthcare providers, increases or decreases.  
In studies assessing the Cervarix® vaccine, vaccine recipients reported more 
overall adverse events (injection site and systemic) when compared to placebo 
recipients (92% versus 88% respectively; Villa et al., 2005). Investigators 
of school-based vaccination programs in New South Wales have recently 
estimated the rate of post-Gardasil® vaccine anaphylaxis to be 2.6/ 100,000 
doses administered (95% CI 1.0 - 5.3 per 100,000; Brotherton et al., 2008). In 
comparison, one case of anaphylaxis was identified in a 2003 meningococcal 
C vaccination program (anaphylaxis rate of 0.1/100,000 doses administered; 
95% CI 0.003 -- 0.7). Overall research results revealed that the estimated rate of 
anaphylaxis following HPV vaccination was significantly higher than the rate 
following comparable school-based vaccination programs. 
 Other research suggests that the immuno-stimulatory properties of 
the Gardasil® vaccine may influence the occurrence and severity of CNS 
demyelination in patients with known multiple sclerosis, however no direct 
conclusions have been made regarding recommendations for the immunization 
of these persons (Sutton, Lahoria, Tan, Clouston, & Barnett, 2009). Two post-
vaccination cases of status epilepticus with myoclonus (repeated and prolonged 
seizures and loss of consciousness) in Spain have recently been reviewed by 
the Committee for Medicinal Products for Human Use (CHMP) and have been 
determined to be unlikely associated with the Gardasil® vaccine (European 
Medicines Agency [EMEA], 2009). The EMEA has also issued a report 
concerning the unexpected deaths of two females in the European Union (EU), 
stating that both occurred post-Gardasil® vaccination, but the causes of death 
could not be identified (EMEA, 2008).   
 As of December 31, 2008, more than 23 million quadrivalent HPV 
doses had been distributed in the U.S. (Slade et al., 2009). Postlicensure data 
from the U.S. Vaccine Adverse Event Reporting System (VAERS) for the 2.5 
years following Gardasil® licensure has recently been released and analyzed. 
At the time of release, VAERS had received 12,424 reports of adverse events 
following immunization (AEFI) yielding a report rate of 53.9/100,000 doses. 
Reports were submitted by the following: manufacturer (68%), providers (17%), 
“others” (11%), patients or parents (4%), and state health clinics (1%). Due to 
insufficient information, 7,561 (89%) of the manufacturer reports could not be 
further reviewed. Gardasil® was the only vaccine identified in 80% of reports 
(9,910 of 12,424). Females accounted for 97% (12,039 of 12,424) of reports, 
and of the 47 reports on male vaccine recipients, 53% (25 of 47) were classified 
as unintentional and 36% (17 of 47) as off-label use. The majority (61%) of the 
9,396 reports (77%) listing dose information occurred after the first dose with 
25% reported after the second dose, 13% after the third dose, and 1% reported 
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after inadvertently receiving 4 or more doses. There was an average of 3.7 
codes per report (range, 2--10; 46,932 codes for 12,424 reports) with the most 
frequently reported AEFIs including syncope (n = 1,847, 15%), dizziness (n = 
1,763, 14%), nausea (n = 1,170, 9%), headache (n = 957, 8%), and injection site 
reactions (n = 926, 7.5%). 
 Of the 32 total reports of death, 20 (62.5%) had information available 
to permit further evaluation. Seventy percent of cases (14 reports) were after 
quadrivalent HPV alone, and the mean age was 18 years (median, 17 years; 
range, 12-26 years); no clustering of age was determined. Causes of death were 
generally classified as the following: unexplained (4), diabetic ketoacidosis 
(2), prescription drug abuse (1), juvenile amyotropic lateral sclerosis (1), 
meningoencephalitis (1), influenza B viral sepsis (1), pulmonary embolism (3), 
cardiac-related deaths (6), and idiopathic seizure disorder (2). 
Although data suggests no major complications during pregnancy, the vaccines 
are not currently approved for pregnant women (Dawar, Dobson & Deeks, 
2007). Data from 1,901 women who became pregnant during the Gardasil® 
trials indicates similar results of pregnancy related adverse effects among 
vaccine and placebo recipients (4.2% and 4.3%, respectively; Merck Frost 
Canada, Ltd., 2006). Persons concerned with the safety of the vaccine can be 
reassured by the CDC who continues to monitor vaccine-related side effects 
and currently maintains that the vaccination is safe and effective for the 
recommended populations (CDC, 2010c).  
Future Directions
 With the help of recent funding from the Bill & Melinda Gates 
Foundation along with the National Institutes of Health (NIH), Richard 
Schlegel, a primary researcher behind the development of Cervarix®, and his 
team now have $3.5 million to use towards the creation of a new vaccine that 
will be both preventative and therapeutic (Bloom, 2005). The team also plans to 
combat transportation issues with the current vaccine formula (which must be 
kept frozen) by developing a powder formula which can be easily transported to 
developing countries and reconstituted with water. Researchers estimate that the 
development of a more inclusive prophylactic vaccine could potentially lead to 
a 70% or more reduction of cervical cancer risk (Saslow et al., 2007). According 
to Saslow and colleagues (2007):  
 Ultimately, cervical cancer rates will depend on (1) the degree of   
 vaccination coverage of the at-risk population; (2) the number of   
 carcinogenic HPV types targeted by the prophylactic vaccine; (3) the   
 durability of protection; and (4) whether the medical community and   
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 the public continue to follow recommended screening guidelines (p.   
 18).
The possibility of continued protection from a HPV vaccine booster shot is 
being researched, but the reduction of HPV incidence will depend upon the 
percent of the population receiving the booster shot as well as the efficacy of the 
booster (Saslow et al., 2007). 
 An assessment of the cost-effectiveness of Gardasil® by Kulasingam 
and colleagues (2008) estimated that the vaccination of 100,000 girls would 
result in a reduction of 400 cases of cervical cancer, 6,700 cases of cervical 
intraepithelial neoplasia, and 4,750 cases of genital warts, suggesting that the 
addition of HPV vaccine programs to current screening measures could prove 
to be a cost-effective way to aid in the reduction of cervical cancer rates. In 
addition, investigators at Stanford University estimated that if the Gardasil® 
vaccine were implemented nationally in the U.S. to all 12 year old girls, 1,340 
cancer-related deaths could be prevented over the target population’s lifetime 
(Sanders & Taira, 2003). Researchers assessed factors such as lowered estimates 
of vaccine efficacy (40%) and potentially required reoccurring booster shots 
and concluded that the vaccine would be cost-effective even under these 
circumstances. 
 According to Insinga, Glass, and Rush (2004), annual costs in 1998 for 
cervical HPV-related disease in the U.S. are estimated to total about $3.4 billion 
including the following expenditures (a) $2.1 billion for routine screening (b) 
$300 million for false positives (c) $600 million for treatment of cervical pre-
cancerous conditions and (d) and $350 million for treatment of invasive cancer. 
Estimates indicated that this value had grown to $5 billion by 2005 (Insinga, 
2006). In addition, HPV-related health care costs were greater for HPV than 
other sexually transmitted infections including Hepatitis B, genital herpes, and 
Chlamydia (Insinga et al., 2004). A recent assessment by the ACS indicated that 
about 30 women/day were diagnosed with cervical cancer in the United States in 
2008 and the cost of cervical cancer screening and treatment is estimated to be 
as high as $6 billion/year in the U.S. (Saslow et al., 2007).
Conclusion
 A systematic review of the available literature reveals that HPV and 
the accompanying vaccinations have significant public health implications in 
the U.S. and abroad. Additional research is needed to assess the epidemiological 
impact of large-scale vaccine implementation including the prevention of 
HPV-related illnesses as well as the potential negative effects associated with 
vaccination. As findings of ongoing empirical assessments become available, 
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additional HPV-related health policies will be needed to ensure that the best 
evidence-based public health practices are enacted.
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